Compared to Estimates, Bausch (BHC) Q3 Earnings: A Look at Key Metrics

Core Viewpoint - Bausch Health reported strong financial results for the quarter ended September 2024, with revenue and EPS exceeding expectations, indicating positive growth trends in various segments [1][3]. Financial Performance - Total revenue for Bausch Health reached $2.51 billion, marking a 12.2% increase year-over-year and surpassing the Zacks Consensus Estimate of $2.43 billion by 3.33% [1]. - Earnings per share (EPS) were reported at $1.12, an increase from $1.03 in the same quarter last year, representing an EPS surprise of 8.74% [1]. Segment Performance - Bausch + Lomb revenues totaled $1.20 billion, slightly below the average estimate of $1.21 billion, but still reflecting an 18.8% year-over-year increase [3]. - Revenues excluding Bausch + Lomb were $1.31 billion, exceeding the average estimate of $1.22 billion, with a year-over-year growth of 6.7% [3]. - Diversified Products generated $269 million, surpassing the average estimate of $248.43 million, with a year-over-year change of 3.9% [3]. - Solta Medical revenues reached $112 million, exceeding the estimate of $99.70 million, showing a significant year-over-year increase of 34.9% [3]. - International revenues were $291 million, above the average estimate of $280.64 million, reflecting a 5.8% year-over-year growth [3]. - Salix revenues amounted to $642 million, exceeding the average estimate of $590.26 million, with a year-over-year increase of 4.6% [3]. - Product sales totaled $2.48 billion, surpassing the average estimate of $2.40 billion, indicating a 12.2% year-over-year change [3]. - Other revenues were reported at $28 million, exceeding the estimate of $23.07 million, with a year-over-year increase of 12% [3]. - Bausch + Lomb Vision Care revenues were $684 million, slightly below the estimate of $686.92 million, with a year-over-year change of 5.6% [3]. - Bausch + Lomb Surgical revenues were $206 million, compared to the average estimate of $213.09 million, reflecting an 11.4% year-over-year increase [3]. - Bausch + Lomb Ophthalmic Pharmaceuticals revenues reached $306 million, slightly below the estimate of $312.07 million, but showing a substantial year-over-year increase of 75.9% [3]. Stock Performance - Bausch shares have returned -1.3% over the past month, contrasting with the Zacks S&P 500 composite's +1.8% change, indicating underperformance relative to the broader market [4].